Zimmer Biomet Holdings Inc (NYSE:ZBH) announced a quarterly dividend on Thursday, June 11th, RTT News reports. Stockholders of record on Monday, June 29th will be given a dividend of 0.24 per share by the medical equipment provider on Friday, July 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.81%. The ex-dividend date is Friday, June 26th.
Zimmer Biomet has a payout ratio of 23.3% meaning its dividend is sufficiently covered by earnings. Analysts expect Zimmer Biomet to earn $7.64 per share next year, which means the company should continue to be able to cover its $0.96 annual dividend with an expected future payout ratio of 12.6%.
ZBH stock opened at $118.22 on Thursday. The company has a market cap of $26.00 billion, a P/E ratio of 65.32, a PEG ratio of 4.81 and a beta of 1.32. Zimmer Biomet has a twelve month low of $74.37 and a twelve month high of $161.11. The company has a quick ratio of 1.03, a current ratio of 1.69 and a debt-to-equity ratio of 0.65. The business has a fifty day moving average of $124.61 and a 200-day moving average of $130.68.
Several analysts have issued reports on ZBH shares. Guggenheim lowered Zimmer Biomet from a “buy” rating to a “neutral” rating in a research note on Tuesday, April 28th. Wells Fargo & Co upped their price objective on Zimmer Biomet from $124.00 to $132.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. Raymond James upped their price objective on Zimmer Biomet from $136.00 to $140.00 and gave the company a “strong-buy” rating in a research note on Tuesday, May 12th. UBS Group dropped their price objective on Zimmer Biomet from $180.00 to $165.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Finally, Evercore ISI downgraded Zimmer Biomet from an “outperform” rating to an “in-line” rating in a research report on Sunday, April 19th. Five analysts have rated the stock with a hold rating, twenty-one have given a buy rating and two have given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $147.72.
In other news, insider Sang Yi sold 3,000 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $125.38, for a total value of $376,140.00. Following the completion of the sale, the insider now directly owns 2,506 shares in the company, valued at approximately $314,202.28. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Bryan C. Hanson bought 1,000 shares of Zimmer Biomet stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average price of $113.00 per share, with a total value of $113,000.00. Following the completion of the purchase, the chief executive officer now owns 54,568 shares in the company, valued at $6,166,184. The disclosure for this purchase can be found here. 0.44% of the stock is owned by company insiders.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Featured Article: Relative Strength Index
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.